



September 09, 2020

To

National Stock Exchange of India Limited,

Compliance Department, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, Maharashtra, India To

BSE Limited,

Compliance Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001, Maharashtra, India

Dear Sirs,

<u>Subject: Intimation regarding the disclosure received from the acquirer in terms of SEBI</u> (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Stock Code: BSE - 539787, NSE - HCG

<u>Reference: Regulation 29 (1) and 29 (2) of SEBI (Substantial Acquisition of Shares and Takeovers)</u> Regulations, 2011

Pursuant to Regulation 29 (1) and 29 (2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we submit herewith copy of disclosure received from Aceso Company Pte. Ltd ("the Acquirer"), with respect to the acquisition of 26,048,478 equity shares of the Company pursuant to mandatory tender offer, on September 08, 2020.

Kindly take this on record and acknowledge receipt of this intimation.

Thanking you,

For HealthCare Global Enterprises Limited

mount

Sunu Manuel

Company Secretary & Compliance Officer

Enclosure: as above

Aceso Company Pte. Ltd. (UEN. 202010289R)

38 Beach Road #29-11 South Beach Tower Singapore 189767

9 September 2020

National Stock Exchange of India Limited,

Compliance Department, Exchange Plaza, Bandra Kurla Complex,

Bandra (East), Mumbai - 400051,

Maharashtra, India

E-mail: <u>takeover@nse.co.in</u> Stock Code: NSE – HCG

BSE Limited,

Compliance Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai -400001, Maharashtra, India

E-mail: corp.relations@bseindia.com

Stock Code: BSE – 539787

HealthCare Global Enterprises Limited,

Compliance Officer, #8, 'HCG Towers', P. Kalinga Rao Road Sampangi Ram Nagar, Bangalore - 560 027, India

E-mail: sunumanuel@hcgel.com

Dear Sir/Madam,

Subject: Disclosure under Regulations 29(1) and (2) of Securities and Exchange Board

of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 in respect of acquisition of equity shares and warrants of HealthCare Global

Enterprises Limited.

This is to inform you that ACESO COMPANY PTE. LTD has acquired 26,048,478 equity shares in HealthCare Global Enterprises Limited pursuant to the mandatory tender offer on 8 September 2020.

In view of the above, please find attached the requisite disclosure under Regulations 29(1) and 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended.

Kindly take the intimation on record and acknowledge receipt of the same.

Thanking you,

For ACESO COMPANY PTE. LTD

Name: Tan Ting Luen

Designation: Director

Aceso Company Pte. Ltd. (UEN. 202010289R) 38 Beach Road #29-11 South Beach Tower Singapore 189767

Disclosures under Regulations 29(1) and 29 (2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Part A – Details of the Acquisition

Name of the Target Company (TC)	HealthCare Global Enterprises Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	 Acquirer – Aceso Company Pte. Ltd. (Acquirer); PAC 1 – Aceso Investment Holdings Pte. Ltd.; PAC 2 – CVC Capital Partners Asia V L.P.; PAC 3 – CVC Capital Partners Investment Asia V L.P.; and PAC 4 – CVC Capital Partners Asia V Associates L.P. 		
Whether the Acquirer belongs to Promoter/ Promoter group	Yes.		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	National Stock Exchange of India Limited BSE Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of: a) Shares carrying voting rights	36,573,455 Equity Shares of face value INR 10	29.20 %	26.36%
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/	-	-	-
c) Voting rights (VR) otherwise than by	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	11,503,468 Warrants convertible into Equal number of Equity Shares.	-	8.29%
e) Total (a+b+c+d)	48,076,923	29.20%	34.65%

Aceso Company Pte. Ltd. (UEN. 202010289R) 38 Beach Road #29-11 South Beach Tower Singapore 189767

Details of acquisition			
a) Shares carrying voting rights acquired	26,048,478 Equity Shares of face value INR 10	20.79%	18.77%
b) VRs acquired otherwise than by equity shares.	1	1	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	-	-	-
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
e) Total (a+b+c+/-d)	26,048,478	20.79%	18.77%
After the acquisition, holding of acquirer along with PACs of: a) Shares carrying voting rights	62,621,933 Equity Shares of face value INR 10	49.99%	45.13%
b) VRs otherwise than by equity shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	11,503,468 Warrants convertible into Equal number of Equity Shares.	-	8.29%

Aceso Company Pte. Ltd. (UEN. 202010289R) 38 Beach Road #29-11 South Beach Tower Singapore 189767

			1	
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)				
e) Total (a+b+c+d)	74,125,401	49.99%	53.42%	
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance,	Mandatory Tender Offer			
etc.)				
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	N.A.			
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	8 September 2020			
Equity share capital / total voting capital of the TC before the said acquisition	125,264,084 equity shares having a face value of INR 10 each			
Equity share capital/ total voting capital of the TC after the said acquisition	125,264,084 equity shares having a face value of INR 10 each			
Total diluted share/voting capital of the TC after the said acquisition	138,767,552 equity shares having a face value of INR 10 each (assuming full conversion of 11,503,468 Series A warrants and 2,000,000 Series B warrants)			